ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC).
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOxaliplatin is widely used to treat gastrointestinal and hepatobiliary cancers, yet hypersensitivity reactions (HSRs) remain a significant safety concern in oncology. Although international guidelines address anaphylaxis and chemotherapy-related HSRs, existing recommendations are fragmented and often lack specificity for oxaliplatin or for hepatic arterial infusion chemotherapy (HAIC), for which evidence is limited. This study aimed to retrieve and synthesize the best available evidence to support standardized management of oxaliplatin-induced HSRs.
methodsGuided by the evidence-based "6S" model, we conducted a hierarchical, top-down search of international and domestic databases for clinical guidelines, clinical decision tools, evidence summaries, systematic reviews, and expert consensus documents published from January 2020 to February 2025. Two trained reviewers independently screened studies, appraised quality using the AGREE II and JBI instruments, and extracted and synthesized relevant evidence.
resultsEight documents met the inclusion criteria, including five clinical guidelines, two systematic reviews, and one expert consensus. Twenty-five evidence statements were synthesized across seven domains: (1) risk factor assessment, (2) preventive measures, (3) patient and caregiver education, (4) symptom recognition and severity assessment, (5) acute management strategies, (6) monitoring and follow-up, and (7) documentation and reporting of adverse drug reactions. Attention was given to distinguishing infusion-related reactions, immune-mediated hypersensitivity, and true anaphylaxis based on clinical presentation and diagnostic criteria rather than severity grading scales alone.
conclusionThis review offers the most comprehensive synthesis to date of the best available evidence for managing oxaliplatin-induced HSRs and highlights a significant gap in HAIC-specific guidance. The findings integrate global recommendations with emerging clinical insights and provide an evidence-informed framework to support oncology teams in improving the safety, consistency, and standardization of oxaliplatin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.